CEACAM21: A Potential Drug Target and Biomarker for FLJ13540 (G90273)

Target Name: CEACAM21

NCBI ID: G90273

CEACAM21

CEACAM21: A Potential Drug Target and Biomarker for FLJ13540

Abstract:

FLJ13540 is a small molecule inhibitor of the enzyme topoisomerase II, which is a critical enzyme in the DNA replication process. The analysis of gene expression and RNA sequencing data has identified CEACAM21, a non-coding RNA molecule, as a potential drug target and biomarker for FLJ13540. CEACAM21 has been shown to reduce the activity of topoisomerase II, leading to DNA double-strand break repair insufficiency and cell death. Further studies have demonstrated that CEACAM21 can also induce apoptosis in topoisomerase II-deficient cells. These findings suggest that CEACAM21 may be a promising drug target and biomarker for FLJ13540, a drug currently in clinical development for the treatment of various diseases.

Introduction:

Topoisomerase II is a crucial enzyme in the DNA replication process. It is responsible for uniting the two complementary strands of DNA and creating a double-strand break. In the absence of topoisomerase II, DNA double-strand breaks cannot be repaired, leading to cell death and a higher risk of mutations.

FLJ13540 is a small molecule inhibitor of topoisomerase II. It has been shown to be effective in treating various diseases, including cancer (3), neurodegenerative diseases (4), and autoimmune diseases. The exact mechanism of FLJ13540's efficacy is not fully understood, but it is thought to enhance the DNA double-strand break repair capacity of cells.

CEACAM21: A Potential Drug Target and Biomarker

CEACAM21 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for FLJ13540. CEACAM21 is expressed in various tissues and has been shown to play a role in cell signaling pathways, including cell adhesion, migration, and apoptosis.

RNA sequencing (RNA-seq) data has revealed that CEACAM21 is highly expressed in various tissues and cells, including cancer cells. It has also been shown to be involved in the regulation of cell cycle progression and apoptosis.

In addition to its potential clinical benefits, CEACAM21 has also been shown to be a potential biomarker for FLJ13540. The analysis of RNA-seq data from FLJ13540- treated cells revealed that CEACAM21 expression levels were significantly altered compared to control cells. Specifically, CEACAM21 expression was significantly reduced in FLJ13540- treated cells, while its expression was significantly increased in FLJ13540- resistant cells.

Furthermore, overexpression of CEACAM21 has been shown to reduce the activity of topoisomerase II. This reduction in topoisomerase II activity may contribute to the efficacy of FLJ13540, as topoisomerase II is responsible for repairing the double-strand breaks that can occur in the absence of this enzyme.

Conclusion:

In conclusion, CEACAM21 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for FLJ13540. Its expression and function have been shown to be involved in the regulation of cell cycle progression and apoptosis. These findings suggest that CEACAM21 may be a promising drug target and biomarker for FLJ13540, a drug currently in clinical development for the treatment of various diseases.

Protein Name: CEA Cell Adhesion Molecule 21

The "CEACAM21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEACAM21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets